Homburg

• SIOP RANDOMET 2017 Recruiting
  2023-508926-91-00 5 2019-12-05 Stage IV childhood renal tumour with pulmonary +/- non-pulmonary metas
• LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting
  2023-508101-24-00 5 2019-08-01 Lymphoblastic lymphoma
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• Paediatric Hepatic International Tumour Trial Recruiting
  2024-516110-38-00 5 2018-03-06 Hepatoblastoma and Hepatocellular Carcinoma
• SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependym … Recruiting
  2024-512222-28-00 10 2015-06-02 Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-038) Ended recruitment
  2025-521970-33-00 5 2025-12-19 ​​Pulmonary Arterial Hypertension (PAH)
• A Phase 1/2 Study to Evaluate ALN-6400 in Adult Healthy Volunteers and Adult Patients with HHT Ended recruitment
  2025-522510-23-00 9 2025-12-15 Hereditary Hemorrhagic Telangiectasia (HHT)
• A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC Ended recruitment
  2024-516051-40-00 4 2025-06-10 Small Cell Lung Cancer (SCLC)
• A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive … Ended recruitment
  2024-510908-37-00 5 2024-08-28 KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
• Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell … Ended recruitment
  2023-503594-38-00 1 2024-07-15 Select B-Cell malignancies.
• A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei … Ended recruitment
  2023-508306-15-00 5 2024-06-26 Alzheimer’s Disease
• Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended recruitment
  2022-500571-32-00 4 2024-05-15 Early-Stage Unfavorable Classical Hodgkin Lymphoma
• A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended recruitment
  2023-506669-70-00 5 2024-04-30 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
• ATHENA: A research study looking into how ziltivekimab works compared to placebo in people with heart failure and inflammation Ended recruitment
  2023-506988-34-00 5 2024-03-27 Heart failure with mildly reduced or preserved ejection fraction and s
• A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus E … Ended recruitment
  2023-506821-12-00 5 2023-10-12 Estrogen Receptor (ER)-Positive, HER2-Negative, Locally Advanced or Me
• Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma Ended recruitment
  2023-503652-27-00 5 2023-10-06 Melanoma
• Combined Pembrolizumab and Lenvatinib after definitive Chemoradiation of locally advanced HNSCC in PD-L1 positive patients (CPS≥1) Ended recruitment
  2024-516536-10-00 4 2023-05-25 Locally advanced head and neck squamous cell carcinoma
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu … Ended recruitment
  2022-500014-26-00 5 2022-06-24 Locally-Advanced unresectable or Metastatic breast cancer (MBC)
• A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca … Ended recruitment
  2023-509631-37-00 5 2022-01-18 "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Bre
• A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr … Ended recruitment
  2023-508248-23-00 5 2021-11-26 Non-alcoholic steatohepatitis (NASH)
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended recruitment
  2023-506926-35-00 5 2021-09-24 Atherosclerotic cardiovascular disease, chronic kidney disease and sys
• Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Ended recruitment
  2024-514473-21-00 5 2021-06-21 Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer

Showing 97–120 of 180 trials